Dimerix Expands Post-Trial Access to Kidney Disorder Drug for Eligible Patients

MT Newswires Live

Yesterday

Dimerix (ASX:DXB) said eligible patients with focal segmental glomerular sclerosis who complete treatment in its phase three clinical trial and open-label extension study will be able to continue receiving investigational therapy DMX-200 through post-trial access programs in key territories, according to a Thursday Australian bourse filing.

The company said access will be provided to patients whose treating physicians determine that ongoing therapy is appropriate and that no suitable alternative is available through expanded access, compassionate use, special access, or other applicable regulatory pathways, subject to local regulations, per the filing.

The company's commercial partners will handle market access and supply costs for DMX-200 in their territories, while it will assume these responsibilities in territories where no commercialization partner has been appointed, the filing added.

The company's shares rose past 2% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2650317943"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650317943\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650317943?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 11:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650317943","market":"nz","top_or_hot":-1,"title":"Dimerix Expands Post-Trial Access to Kidney Disorder Drug for Eligible Patients","media":"MT Newswires Live","content":"<html><body><p> Dimerix (ASX:DXB) said eligible patients with focal segmental glomerular sclerosis who complete treatment in its phase three clinical trial and open-label extension study will be able to continue receiving investigational therapy DMX-200 through post-trial access programs in key territories, according to a Thursday Australian bourse filing.</p><p>The company said access will be provided to patients whose treating physicians determine that ongoing therapy is appropriate and that no suitable alternative is available through expanded access, compassionate use, special access, or other applicable regulatory pathways, subject to local regulations, per the filing.</p><p>The company's commercial partners will handle market access and supply costs for DMX-200 in their territories, while it will assume these responsibilities in territories where no commercialization partner has been appointed, the filing added.</p><p>The company's shares rose past 2% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix Expands Post-Trial Access to Kidney Disorder Drug for Eligible Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix Expands Post-Trial Access to Kidney Disorder Drug for Eligible Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-09 11:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dimerix (ASX:DXB) said eligible patients with focal segmental glomerular sclerosis who complete treatment in its phase three clinical trial and open-label extension study will be able to continue receiving investigational therapy DMX-200 through post-trial access programs in key territories, according to a Thursday Australian bourse filing.</p><p>The company said access will be provided to patients whose treating physicians determine that ongoing therapy is appropriate and that no suitable alternative is available through expanded access, compassionate use, special access, or other applicable regulatory pathways, subject to local regulations, per the filing.</p><p>The company's commercial partners will handle market access and supply costs for DMX-200 in their territories, while it will assume these responsibilities in territories where no commercialization partner has been appointed, the filing added.</p><p>The company's shares rose past 2% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4212","symbol_name":"包装食品与肉类","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650317943","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650317943","pubTimestamp":1783569144,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dimerix  said eligible patients with focal segmental glomerular sclerosis who complete treatment in its phase three clinical trial and open-label extension study will be able to continue receiving investigational therapy DMX-200 through post-trial access programs in key territories, according to a Thursday Australian bourse filing.The company said access will be provided to patients whose treating physicians determine that ongoing therapy is appropriate and that no suitable alternative is available through expanded access, compassionate use, special access, or other applicable regulatory pathways, subject to local regulations, per the filing.The company's commercial partners will handle market access and supply costs for DMX-200 in their territories, while it will assume these responsibilities in territories where no commercialization partner has been appointed, the filing added.The company's shares rose past 2% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4212":"包装食品与肉类","BK7067":"生物科技","DXB.AU":"DIMERIX LTD","BK7501":"新冠治疗股","POST":"Post Holdings","BK7508":"医药生物股"},"translate_title":"Dimerix扩大了符合条件的患者在试验后获得肾脏疾病药物的机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB.AU":1,"POST":1.5},"content_text":"Dimerix (ASX:DXB) said eligible patients with focal segmental glomerular sclerosis who complete treatment in its phase three clinical trial and open-label extension study will be able to continue receiving investigational therapy DMX-200 through post-trial access programs in key territories, according to a Thursday Australian bourse filing.The company said access will be provided to patients whose treating physicians determine that ongoing therapy is appropriate and that no suitable alternative is available through expanded access, compassionate use, special access, or other applicable regulatory pathways, subject to local regulations, per the filing.The company's commercial partners will handle market access and supply costs for DMX-200 in their territories, while it will assume these responsibilities in territories where no commercialization partner has been appointed, the filing added.The company's shares rose past 2% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}